Effect of Transcranial Direct Current Brain Stimulation of the Motor Cortex on Chemotherapy-Induced Nausea and Vomiting in Female Patients with Breast Cancer

Abstract Objective Chemotherapy-induced nausea and vomiting (CINV) is an adverse outcome associated with chemotherapy and is sometimes difficult to manage. This study aimed to examine the impact of a single session of transcranial direct current brain stimulation (tDCS; 2 mA) over the motor cortex f...

Full description

Saved in:
Bibliographic Details
Published in:Pain medicine (Malden, Mass.) Mass.), 2022-03, Vol.23 (3), p.571-578
Main Authors: Kamal, Shereen Mamdouh, Elhusseini, Nayria Mahmoud, Sedik, Mayada Fawzy, Mohamad, Mohamad F, Khedr, Eman Mohamed Hussein, Kotb, Hassan Ibraheem Mohamed
Format: Article
Language:English
Subjects:
Antiemetics - therapeutic use
Antineoplastic Agents - adverse effects
Breast cancer
Breast Neoplasms - drug therapy
Cancer therapies
Chemotherapy
Cortex (motor)
Double-Blind Method
Female
Humans
Motor Cortex
Nausea
Nausea - chemically induced
Nausea - therapy
Patients
Prospective Studies
Transcranial Direct Current Stimulation
Vomiting
Vomiting - chemically induced
Vomiting - therapy
Well being
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective Chemotherapy-induced nausea and vomiting (CINV) is an adverse outcome associated with chemotherapy and is sometimes difficult to manage. This study aimed to examine the impact of a single session of transcranial direct current brain stimulation (tDCS; 2 mA) over the motor cortex for 20 minutes before chemotherapy in patients receiving a highly emetogenic chemotherapy. Study Design Prospective randomized double-blind sham-controlled study. Setting Academic medical center. Method Sixty patients with breast cancer who were scheduled for chemotherapy treatment were selected and allocated randomly into two equal groups: a stimulation group and a sham group. tDCS was implemented over the primary motor area (M1) (2 mA) for 20 minutes. Patients’ nausea was measured by a cumulative index of nausea, a visual analog scale for nausea (VAS-N), episodes of vomiting, and the Edmonton Symptoms Assessment Scale (ESAS) to assess symptoms like pain, malaise, and sense of well-being. Evaluation was done before stimulation and every 24 hours for 72 hours after the end of infusion of chemotherapy. Results The tDCS group showed a reduction in the cumulative index of nausea (P 
ISSN:1526-2375
1526-4637
DOI:10.1093/pm/pnab313